Drug Profile
Recombinant haemoglobin 3011
Alternative Names: Recombinant haemoglobin 3011 - Baxter Healthcare; rHb3011Latest Information Update: 02 May 2006
Price :
$50
*
At a glance
- Originator Baxter Healthcare Corporation
- Class Plasma expanders
- Mechanism of Action Haemoglobin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypovolaemia
Most Recent Events
- 31 Dec 2003 Discontinued - Phase-I for Hypovolaemia in USA (Parenteral)
- 03 Dec 2003 Phase-I clinical trials in Hypovolaemia in USA (Parenteral)
- 06 Dec 2001 No-Development-Reported for Hypovolaemia in USA (Parenteral)